Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Cision · Oct 3, 2026
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress Cision · Oct 3, 2026
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL Cision · Oct 3, 2026
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo Cision · Oct 2, 2026
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Cision · Oct 2, 2026
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy Cision · Oct 2, 2026
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease Cision · Oct 1, 2026
Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer Cision · Oct 1, 2026
Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering Cision · Oct 1, 2026
